Astellas' Prosidion Subsidiary Sells Dipeptidyl Peptidase IV (DPP-IV) Patent Estate and Associated Royalty Interest to Royalty Pharma for USD 609 Million - Drugs.com MedNews
Links shared publicly online about this topic.
- 181total visits
Astellas' Prosidion Subsidiary Sells Dipeptidyl Peptidase IV (DPP-IV) Patent Estate and Associated Royalty Interest to Royalty Pharma for USD 609 Million - Drugs.com MedNews
Jun 30, 2011 - Astellas Pharma Inc. (TOKYO 4503)( Astellas ) announced today that Prosidion s patent estate and associated royalty stream relating to the use of
View full resource at drugs.com
Tags: Drug, Pharma, Astellas Pharma
Most Recently Shared on June 30, 2011 at 12:06 pm By:
Astellas' Prosidion Subsidiary Sells Dipeptidyl Peptidase IV (DPP-IV) Patent Estate and Associated Royalty... http://bit.ly/lcPT8a #drug
Astellas' Prosidion Subsidiary Sells Dipeptidyl Peptidase IV (DPP-IV) Patent Estate and Associated Royalty Interest to Royalty Pharma for USD 609 Million - MarketWatch
marketwatch.com — “Astellas' Prosidion Subsidiary Sells Dipeptidyl Peptidase IV (DPP-IV) Patent Estate and Associated Royalty Interest to Royalty Pharma for USD 609 Million - MarketWatch” View full resource at marketwatch.com
Most Recently Shared on June 30, 2011 at 11:58 am By:
Lisa Jarvis Science Enthusiast
Astellas subsidiary Prosidion sells DPP-IV inhibitor (for type 2 diabetes) patent estate to Royalty Pharma for $609m: http://t.co/9AmdbBP
Advertisement
